Почетна › Рак јетре (хепатоцелуларни карцином) › Пенсилванија
Kliničke studije za Рак јетре (хепатоцелуларни карцином) u državi Пенсилванија
29 studija za Рак јетре (хепатоцелуларни карцином) traži učesnike na lokacijama u državi Пенсилванија.
Gradovi u državi Пенсилванија
Zvanični tekst studije (na engleskom)
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06698250Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Lehigh Valley Hospital, Allentown
Тражи се учесникОпсервациона студија
Узраст 22 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT06486454DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
- University of Pennsylvania, Philadelphia
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07807475A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Pittsburgh
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06600321Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06811116A Phase 1 Study of the Safety and Tolerability of CTX-10726
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07419841Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Philadelphia
- Research Site, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06921785Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- AHN Allegheny General Hospital, Pittsburgh
- AHN Cancer Institute at Allegheny General Hospital, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07227012FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT05919264Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483National Liver Cancer Screening Trial
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 4
Узраст од 18 до 85 · Оба пола · Ажурирано 25. 9. 2026. · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06427941Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT07166406Molecular Basis of Pediatric Liver Cancer
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Тражи се учесникОпсервациона студија
Узраст од 0 до 99 · Оба пола · Ажурирано 10. 8. 2026. · NCT03959800Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Allegheny General Hospital, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 8. 2026. · NCT05168163A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
Тражи се учесникФаза 2
Узраст 8 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05503797Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT04114136Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Тражи се учесник
Узраст од 18 до 75 · Оба пола · Ажурирано 17. 6. 2026. · NCT05486572Y-90 Treatment Response Using Transarterial Radioembolization
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT07145801Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1/2
Узраст од 20 до 99 · Оба пола · Ажурирано 20. 4. 2026. · NCT02174549Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 4. 2026. · NCT07223424Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 16. 4. 2026. · NCT05842174Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 4. 2026. · NCT05733598SBRT With Atezo/Bev for HCC
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1
Узраст од 18 до 99 · Оба пола · Ажурирано 20. 2. 2026. · NCT05488522Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
- Thomas Jefferson Hospital, Philadelphia
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 1. 2026. · NCT05705219Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Penn State Hershey Medical Center, Hershey
- Albert Einstein Healthcare Network, Philadelphia
Тражи се учесникФаза 4
Узраст од 18 до 64 · Оба пола · Ажурирано 22. 1. 2026. · NCT04373564Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 1. 2026. · NCT03539822SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.